IND Enabling Tox Batch

LAXAI Life Sciences is your preferred partner, strategically positioned to support your IND enabling tox batch within a robust CRDMO services framework. Our experienced team skillfully navigates the complexities, ensuring a seamless and successful journey across drug development solutions. This pivotal step paves your way to first-in-human trials.

What is IND Enabling Tox Batch?

The IND enabling toxicology batch represents a crucial phase in drug development where specific batches of a drug candidate are produced and tested for toxicity before proceeding to human trials. This process is essential for assessing the safety profile of your potential therapeutic and satisfying regulatory requirements in pharmaceutical research and development.

Our Expertise

Our core expertise lies in swiftly scaling up by addressing small-scale process challenges. We engage our process development teams early in drug discovery programs, enabling faster scale-up and quick production of IND-enabling non-GMP toxicology batches, ensuring a seamless GMP transition for clinical trials within integrated drug discovery.

Our Offerings

Comprehensive Support

Our experienced team offers comprehensive support for IND tox batches, including scale-up, process development, process safety studies, solid-state characterization, and pre-formulation studies aligned with CRDMO services.

Advanced Scale-up Facilties

Our scale-up facilities are equipped with a wide range of reactors from 20 L to 250 L, supported by advanced analytical infrastructure allowing efficient synthesis of high-quality toxicology batches for small molecule R&D.

Regulatory Insight

Ensuring your toxicology batches meet all regulatory standards for a smooth Investigational New Drug (IND) submission process within drug development programs.

Our Process: An Overview

The transition from IND enabling tox batch to first-in-human batch is a critical step in drug development solutions. Our IND tox batch services encompass: